Kazia Therapeutics (KZIA) Competitors $5.64 -0.07 (-1.23%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends KZIA vs. ALRN, ENTX, XFOR, MURA, IOBT, VHAQ, THTX, DTIL, AADI, and STTKShould you be buying Kazia Therapeutics stock or one of its competitors? The main competitors of Kazia Therapeutics include Aileron Therapeutics (ALRN), Entera Bio (ENTX), X4 Pharmaceuticals (XFOR), Mural Oncology (MURA), IO Biotech (IOBT), Viveon Health Acquisition (VHAQ), Theratechnologies (THTX), Precision BioSciences (DTIL), Aadi Bioscience (AADI), and Shattuck Labs (STTK). These companies are all part of the "pharmaceutical products" industry. Kazia Therapeutics vs. Aileron Therapeutics Entera Bio X4 Pharmaceuticals Mural Oncology IO Biotech Viveon Health Acquisition Theratechnologies Precision BioSciences Aadi Bioscience Shattuck Labs Kazia Therapeutics (NASDAQ:KZIA) and Aileron Therapeutics (NASDAQ:ALRN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, community ranking, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings. Does the MarketBeat Community believe in KZIA or ALRN? Aileron Therapeutics received 134 more outperform votes than Kazia Therapeutics when rated by MarketBeat users. Likewise, 66.98% of users gave Aileron Therapeutics an outperform vote while only 52.67% of users gave Kazia Therapeutics an outperform vote. CompanyUnderperformOutperformKazia TherapeuticsOutperform Votes7952.67% Underperform Votes7147.33% Aileron TherapeuticsOutperform Votes21366.98% Underperform Votes10533.02% Do analysts prefer KZIA or ALRN? Kazia Therapeutics presently has a consensus price target of $20.00, indicating a potential upside of 254.61%. Aileron Therapeutics has a consensus price target of $19.00, indicating a potential upside of 588.41%. Given Aileron Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aileron Therapeutics is more favorable than Kazia Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kazia Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Aileron Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Is KZIA or ALRN more profitable? Kazia Therapeutics' return on equity of 0.00% beat Aileron Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Kazia TherapeuticsN/A N/A N/A Aileron Therapeutics N/A -74.08%-27.93% Do institutionals and insiders believe in KZIA or ALRN? 30.9% of Kazia Therapeutics shares are held by institutional investors. Comparatively, 90.9% of Aileron Therapeutics shares are held by institutional investors. 1.0% of Kazia Therapeutics shares are held by insiders. Comparatively, 5.1% of Aileron Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has higher valuation and earnings, KZIA or ALRN? Kazia Therapeutics has higher revenue and earnings than Aileron Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKazia Therapeutics$1.51M9.86-$13.78MN/AN/AAileron TherapeuticsN/AN/A-$15.73M-$3.12-0.88 Which has more risk & volatility, KZIA or ALRN? Kazia Therapeutics has a beta of 2.08, indicating that its share price is 108% more volatile than the S&P 500. Comparatively, Aileron Therapeutics has a beta of 2.35, indicating that its share price is 135% more volatile than the S&P 500. Does the media favor KZIA or ALRN? In the previous week, Aileron Therapeutics had 5 more articles in the media than Kazia Therapeutics. MarketBeat recorded 5 mentions for Aileron Therapeutics and 0 mentions for Kazia Therapeutics. Aileron Therapeutics' average media sentiment score of 0.92 beat Kazia Therapeutics' score of 0.00 indicating that Aileron Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Kazia Therapeutics Neutral Aileron Therapeutics Positive SummaryAileron Therapeutics beats Kazia Therapeutics on 10 of the 14 factors compared between the two stocks. Ad Crypto Swap Profits[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Kazia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KZIA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KZIA vs. The Competition Export to ExcelMetricKazia TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.89M$6.44B$5.06B$8.82BDividend YieldN/A8.11%5.18%4.07%P/E RatioN/A10.78126.3217.81Price / Sales744.48243.711,179.2574.56Price / CashN/A22.1633.8632.53Price / Book1.145.474.684.68Net Income-$13.78M$153.61M$119.54M$226.08M7 Day Performance7.02%-2.00%-1.83%-1.04%1 Month Performance0.43%-7.46%-3.60%1.04%1 Year Performance-22.21%31.82%31.91%26.28% Kazia Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KZIAKazia Therapeutics1.8636 of 5 stars$5.64-1.2%$20.00+254.6%-26.9%$15.05M$1.51M0.0012ALRNAileron Therapeutics3.5661 of 5 stars$2.76-2.1%$19.00+588.4%+46.0%$59.81MN/A-0.889ENTXEntera Bio2.0329 of 5 stars$1.55-4.9%$10.00+545.2%+112.3%$58.33M$130,000.000.0020Gap UpXFORX4 Pharmaceuticals4.0062 of 5 stars$0.34-8.1%$2.88+744.6%-57.4%$58.06MN/A-4.0980Analyst RevisionMURAMural Oncology3.191 of 5 stars$3.37flat$16.00+374.8%N/A$57.36MN/A0.00119Analyst RevisionIOBTIO Biotech3.3072 of 5 stars$0.82-5.7%$9.33+1,038.2%-16.3%$57.32MN/A0.0030VHAQViveon Health AcquisitionN/A$10.00flatN/AN/A$56.56MN/A0.002High Trading VolumeTHTXTheratechnologiesN/A$1.22+1.7%N/A-10.3%$55.18M$81.76M-12.20140Positive NewsDTILPrecision BioSciences4.0289 of 5 stars$7.18+0.3%$39.50+450.1%-46.6%$54.92M$48.73M119.69200Gap UpAADIAadi Bioscience1.1842 of 5 stars$2.22+0.5%$1.67-24.9%-53.3%$54.72M$25.07M-0.9740STTKShattuck Labs2.8175 of 5 stars$1.11-2.6%$8.67+680.8%-50.7%$54.42M$1.66M0.00100Analyst Revision Related Companies and Tools Related Companies ALRN Alternatives ENTX Alternatives XFOR Alternatives MURA Alternatives IOBT Alternatives VHAQ Alternatives THTX Alternatives DTIL Alternatives AADI Alternatives STTK Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KZIA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kazia Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Kazia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KZIA Stock Alerts